Antibodies News and Research

RSS

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Sex steroids may play a protective role in COVID-19, shows study

A new paper from a UIC researcher shows evidence that suggests sex steroids may play a role in protecting against COVID-19 symptoms.

24 Nov 2020

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

A team of researchers based in Iran have explored the role of micro-RNA in COVID-19. Their study titled, “The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,” was published in the latest issue of the journal International Immunopharmacology.

24 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

Researchers in New York, USA, have found an association of mortality with an early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS), using a highly sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2.

24 Nov 2020

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

FairJourney Biologics S.A (FJB) and IONTAS Limited, leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics.

24 Nov 2020

Early high-titer convalescent plasma prevents 75% of severe COVID-19 in elderly

A promising new clinical study published on the preprint server medRxiv reports that if convalescent plasma with a high titer of antibodies is given early in the course of COVID-19 in elderly patients, the risk of severe illness is reduced by 73%.

24 Nov 2020

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor.

23 Nov 2020

Duke-NUS expert joins international taskforce to study the origins of SARS-CoV-2 virus

Nearly a year since the world first learned of the novel coronavirus disease 2019, COVID-19, many questions remain about SARS-CoV-2, the virus behind this pandemic: Where did it come from, how did it spread so widely and rapidly, and how can we stop similar outbreaks in the future?

23 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).

23 Nov 2020

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

23 Nov 2020

SARS-Cov-2 antibodies are detected up to 3 months after infection, shows study

A new study in health care workers led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation and the Hospital Clínic of Barcelona, shows that IgA and IgM antibodies to SARS-CoV-2 decay quickly, while IgG antibody levels are maintained for at least three months after infection.

23 Nov 2020

Antibodies News and Research

Mild COVID-19 disease may trigger long-term immunity

Sex steroids may play a protective role in COVID-19, shows study

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

Early high-titer convalescent plasma prevents 75% of severe COVID-19 in elderly

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

Duke-NUS expert joins international taskforce to study the origins of SARS-CoV-2 virus

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

SARS-Cov-2 antibodies are detected up to 3 months after infection, shows study

Study suggests neutralizing SARS-CoV-2 antibodies offer protection against reinfection

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

Research reveals T-cell abnormalities in severe COVID-19 cases

UVA researchers discover gene responsible for the metastasis of triple-negative breast cancer

Scientists explain potential reasons for SARS-CoV-2 re-infection

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News